背景:与其他乳腺癌亚型相比,三阴性乳腺癌的特征是预后较差,特别是在预处理的转移性三阴性乳腺癌(mTNBC)的情况下。由于有限的治疗选择和次优的反应率,迫切需要探索新的治疗方案。
方法:一名诊断为mTNBC的48岁女性患者,对多种治疗(包括手术,化疗,和放射疗法),但在我们的临床试验中注册后显示出显着的疗效和远视效果。
方法:三阴性乳腺癌肺转移。
方法:临床试验结合立体定向放疗,免疫疗法,粒细胞-巨噬细胞集落刺激因子,和胸腺素α-1治疗先前治疗过的转移性实体癌。
结果:在本临床试验中实施的联合治疗方案产生了患者的显著疗效,伴随着脓肿效应。根据RECISTv1.1标准,目标病变和3个观察到的病变达到了部分反应。2个周期的免疫治疗后的重新评估扫描显示,靶病变的消退率为-78.97%,观察到的病变的消退率为-56.73%。血液学指标稳定,并且没有明显的骨髓抑制。此外,肿瘤标志物CA-199呈下降趋势.在治疗过程中,患者出现2级皮肤反应,在接受抗过敏治疗后有所改善。没有观察到进一步的不良反应。
结论:该治疗方案可能为mTNBC和其他转移性实体癌患者提供有希望的治疗策略。
BACKGROUND: Triple-negative breast cancer is characterized by a worse prognosis compared with other breast cancer subtypes, especially in the case of pretreated metastatic triple-negative breast cancer (mTNBC). Because of the limited treatment options and suboptimal response rates, there is a pressing need to explore novel treatment protocols.
METHODS: A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
METHODS: Triple-negative breast cancer with lung metastases.
METHODS: The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.
RESULTS: This combined treatment regimen implemented in this clinical trial yielded the patient\'s notable efficacy, accompanied by abscopal effects. The target lesion and the 3 observed lesions achieved a partial response according to the RECIST v1.1 criteria. reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of -78.97% for the target lesion and -56.73% for the observed lesions. Hematological indexes were stable, and there was no apparent myelosuppression. Also, the tumor marker CA-199 exhibited a downward trend. During the course of treatment, the patient experienced a grade 2 skin reaction, which improved after receiving antiallergic treatment. No further adverse effects were observed.
CONCLUSIONS: This treatment regimen may offer a promising treatment strategy for patients with mTNBC and other metastatic solid cancers.